Promoter Proximal Pausing Limits Tumorous Growth Induced by the Yki Transcription Factor in Drosophila

Sanket Nagarkar,* Ruchi Wasnik,* Pravallika Govada,* Stephen Cohen,' and L. S. Shashidhara,*‡
*Indian Institute of Science Education and Research (IISER), Pashan, Pune 411008, ‡Department of Cellular and Molecular Medicine, University of Copenhagen, 2200N, Denmark, and †Ashoka University, Sonepat, Haryana 131029, India

ABSTRACT Promoter proximal pausing (PPP) of RNA polymerase II has emerged as a crucial rate-limiting step in the regulation of gene expression. Regulation of PPP is brought about by complexes 7SK snRNP, P-TEFb (Cdk9/cycT), and the negative elongation factor (NELF), which are highly conserved from Drosophila to humans. Here, we show that RNAi-mediated depletion of bin3 or Hexim of the 7SK snRNP complex or depletion of individual components of the NELF complex enhances Yki-driven growth, leading to neoplastic transformation of Drosophila wing imaginal discs. We also show that increased CDK9 expression cooperates with Yki in driving neoplastic growth. Interestingly, overexpression of CDK9 on its own or in the background of depletion of one of the components of 7SK snRNP or the NELF complex necessarily, and specifically, needed Yki overexpression to cause tumorous growth. Genome-wide gene expression analyses suggested that deregulation of protein homeostasis is associated with tumorous growth of wing imaginal discs. As both Fat/Hippo/Yki pathway and PPP are highly conserved, our observations may provide insights into mechanisms of oncogenic function of YAP—the ortholog of Yki in humans.

KEYWORDS tumorigenesis; Drosophila; Hippo pathway; promoter proximal pausing; transcription regulation in growth and cancer

REGULATION of growth is arguably the most critical phenomenon that establishes size and shape of all tissues, organs, and overall body size in metazoan animals. It is also an important homeostatic process, failure of which is linked to diseases and disorders, particularly cancer in humans. Regulated growth is achieved by an intricate interplay between factors promoting growth (oncogenes) and those suppressing it (tumor suppressors).

Yorkie (Yki), the Drosophila ortholog of the Yes-Associated Protein 1 (YAP1), acts as a transcriptional cofactor that mediates the effects of the Hippo tumor suppressor pathway. The Hippo pathway is highly conserved from Drosophila to humans (Pan 2010). The Hippo (Hpo)/MST kinases and the Warts (Wts)/LATS kinases and their cofactors form kinase cassettes that directly phosphorylate Yki (YAP/TAZ) to regulate protein stability and activity (Zhao et al. 2011). Members of this pathway were initially found to limit tissue growth in Drosophila by limiting Yki activity (Huang et al. 2005; Dong et al. 2007). Consistent with this, YAP overexpression has been reported as a driver of tissue growth and cancer in a mouse model (Dong et al. 2007; Zanconato et al. 2015). In humans, the YAP1 locus was found to be amplified in different types of cancer (Overholtzer et al. 2006; Zender et al. 2006). These findings have sparked a great deal of interest in understanding of regulation of Yki/YAP function.

In Drosophila, Yki regulates expression of regulators of cell growth and survival such as Diap1, dMyc, hantam, etc. Targets of YAP in humans include the EGFR-ligand AREG as well as CTGF, Cyr61 (Johnson and Halder 2014). While these target genes are necessary for growth induced by Yki/YAP activity, they are not sufficient to phenocopy effects of Yki/YAP. This indicates possibility of more regulators that are involved in Yki/YAP induced growth.

We have reported an in vivo screen in Drosophila (Groth et al. 2020), wherein we have identified a large number of
genes, which, when depleted, enhanced growth induced by Yki and EGFR. More importantly, these genes function like classical tumor suppressors as, when downregulated in the background of overexpressed Yki or EGFR, we observed neoplastic growth. Among these, we identified a number of genes involved in the control of promoter proximal transcriptional pausing.

Promoter proximal pausing (PPP) of RNA polymerase (Pol) II has been identified as a key step in transcriptional regulation for many genes, during development and in stem cells (Guenther et al. 2007; Muse et al. 2007; Zeitlinger et al. 2007). At paused loci, after initiation, RNA Pol II translocates through the promoter but then stops at ~30–60 bp from the transcription start site (Kwak and Lis 2013). Productive transcription then requires release from the paused state. PPP is brought about by the negative transcription elongation factor (NELF) and 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB)-sensitivity inducing factor (DSIF) protein complexes, which were identified as factors responsible for DRB sensitivity of transcription elongation (Wada et al. 1998; Yamaguchi et al. 1999). These complexes bind RNA Pol II and halt its progress downstream of the promoter. This pause is alleviated by a positive transcription elongation factor complex (P-TEFb) (Figure 1A), which consists of cyclin T and cyclin dependent kinase-CDK9 (Marshall and Price 1995). Once recruited to the paused complex, CDK9 phosphorylates NELF and DSIF leading to ejection of NELF from the paused complex while DSIF assists Ser-5 phosphorylated RNA Pol II in productive elongation (Jonkers and Lis 2015). The P-TEFb complex is, in turn, regulated through sequestration by 7SK snRNP complex. P-TEFb is required for release paused RNA polymerase II into productive elongation (Kwak and Lis 2013). Sequestration of P-TEFb by 7SK snRNP leads to its unavailability for mediating pause release, which, in turn, regulates transcription elongation via sustained pause of RNA Pol II. Mammalian 7sk-snRNP complex consists of 7sk RNA, Hexitm1/2, Larp7, and MePCE. Drosophila homologs of components of mammalian 7sk-snRNP complex were identified and characterized recently (Nguyen et al. 2012). These include Bin3 (MePCE ortholog), Larp (Larp7 ortholog), Hexitm (HEXIM1/2 ortholog), and d7SK RNA. All are highly conserved at functional levels with their mammalian counterparts. Signaling events of pathways such as ERK, TCR, etc., trigger liberation of P-TEFb. Thus, making sequestration and liberation of P-TEFb a context dependent process that is critical for regulating expression of gene regulation depending on the context.

Interestingly, CDK9 has been shown to be important for transcription of target genes of oncogenes such as Myc (Kanazawa et al. 2003) and YAP (Galli et al. 2015). Here, we present evidence of tumor suppressor function of various components involved in PPP, specifically in the context of elevated Yki activity. Our findings show that factors involved in PPP and its regulation are important to restrict Yki driven growth and to prevent neoplastic transformation in vivo.

Material and Methods

Drosophila strains

The following Drosophila strains are used in this study: ap-Gal4 (Cohen et al. 1992) and UAS-Yki (Huang et al. 2005). The following RNAi stocks were obtained from the Vienna Drosophila RNAi Center and Bloomington Drosophila stock Center: UAS-NelfαRNAi (KK106245, TRIP #32897), UAS-NelfβRNAi (KK108441, TRIP #42547), UAS-NelfβRNAi (TRIP #32835), UAS-NelfδRNAi (KK100009, TRIP #38934, #42931), UAS-bin3RNAi (KK101090, TRIP #41527), UAS-HexitmRNAi (KK100500). UAS-CDK9 was obtained from FlyORF (#F001571).

Spatio-temporal regulation of transgene expression in wing imaginal disc

The apertous enhancer was used to drive expression of Gal4 conditionally in dorsal compartment of wing imaginal discs. Gal4 activity was regulated using Gal80TS, which allows expression of transgenes at permissive temperature of 29°C as against restrictive 18°C temperature. In all experiments, tubulin-Gal80TS was used. Drosophila crosses were allowed to lay eggs for 3 days at 18°C, and were then flipped or discarded. Larvae were then allowed to grow for additional 5 days before switching to temperature of 29°C. At 29°C they were maintained for 4–14 days. All crosses were using tubulin-GAL80TS; ap-GAL4; UAS-GFP. Thus, all experimental crosses had one copy of GFP, while control crosses had two copies of GFP. Detailed methodology is provided in Groth et al. (2020). Larval images were taken in bright field and in GFP channel with a Leica stereomicroscope. Image processing was done using Adobe Photoshop 6 and ImageJ.

Immunohistochemistry

The following primary antibodies were used: rat anti-Ecadherin, mouse anti-MMP1 (Developmental Studies Hybridoma Bank). Rhodamine-phalloidin (ThermoFisher Scientific, Cat no R415) was used to stain actin in tissue.

Third instar larvae were dissected in PBS. Samples were fixed in 4% PFA for 20 min, followed by three 10-min washes in PBT (PBS-Tween20) at room temperature. Then, 5% BSA in PBS was used for blocking followed by overnight incubation in primary antibody at 4°C. Next day, the samples were washed with PBT, three times for 10 min each followed by incubation with secondary antibody for 2 hr at room temperature. Samples were then washed with PBT and stained for DNA using 4’,6-diamidino-2-phenylindole (DAPI; Sigma Aldrich) for 5 min. Wing disc tissue was then mounted on slides in Anti-fade Gold mountant (ThermoFisher Scientific). Imaging was done on a Leica SP8 confocal laser-scanning microscope. Image processing was done using ImageJ and Adobe Photoshop 6. Measurement MMP1 intensities and comparison between different genotypes was carried out using ImageJ, statistical analysis (one-way ANOVA) was done using Prism-Graphpad 5.

RNA-seq

Induction procedure for transgenes was followed as mentioned earlier. Wing imaginal disc tissue was dissected on
4th–5th day after induction for ap > GFP, ap > UAS-Yki, ap > Nelf-A RNAi (KK106245), ap > UAS-Yki, UAS Nelf-A RNAi. Larvae were washed in RNase-, DNase-free ultrapure water (GibCO), and then dissections were done in RNase-, DNase-free PBS (GibCo). Number of wing imaginal discs collected was 150, 70, 150, 25, respectively for ap > GFP, ap > UAS-Yki, ap > Nelf-A RNAi (KK106245), ap > UAS-Yki, and UAS Nelf-A RNAi. Collection was done in TRIzol reagent (ThermoFisher Scientific). Each genotype was collected in three biological replicates. RNA sequencing was done on an Illumina platform.

**RNA-seq data analysis**

RNA-seq analysis was performed using the HISAT 2.0 package protocol as explained in Pertea et al. (2016). To identify significantly differentially expressing genes in different combinations of comparisons, DEseq package and EdgeR were used (Anders and Huber 2010). The entire RNA-seq data set is available on GEO database (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE151935).

The list of genes obtained was then used as input for the web-based tool venny (http://bioinfogp.cnb.csic.es/tools/venny/index.html) to obtain a list of genes that are unique to each genotype, overlapping between all three or combination of any two genotypes.

**Gene ontology analysis**

For gene ontology (GO) and pathway enrichment analysis, we utilized STRING10 (Szklarczyk et al. 2017). We used gene lists that are significantly differentially expressed in single
genotype or a combination of genotypes as mentioned in the results section, as input to the STRING. The output files were downloaded as interaction network and list of genes from input that are enriched in different GO categories or as KEGG pathways.

Data availability

The authors state that all data necessary for confirming the conclusions presented in the article are represented fully within the article. All *Drosophila* stocks are available upon request. RNA-seq data are available at GEO with the accession number: GSE151935. Supplemental material available at figshare: https://doi.org/10.25386/genetics.12689318.

Results

**Depletion 7SK snRNP complex components cooperates with Yki in causing tumorous growth**

Studies using *Drosophila* tumor models have found that larvae containing proliferating tumors are unable to enter pupariation and continue to grow (Gateff et al. 1993). The resulting giant larva phenotype can be used in genetic screens to identify tumor-causing genotypes. We made use of this property to identify candidate genes in a genetic screen for tumor suppressors cooperating with Yki [the entire screen is published elsewhere (Groth et al. 2019)]. We found that RNAi-mediated depletion of *bin3* or *Hexim*, components of the 7SK snRNA complex in combination with Yki overexpression led to massive overgrowth in wing disc tissue and giant larval phenotype (Figure 1B). Wing discs expressing Yki alone show only moderate overgrowth phenotype, and larvae eventually pupate (Figure 1B). Depletion of 7SK snRNP components did not produce overgrowth on their own (Supplemental Material, Figure S1), but only did so when coupled with Yki overexpression. We also did not observe wing disc overgrowth when depletion of 7SK snRNP components in combination with overexpression of other well-known oncoproteins such as epidermal growth factor receptor (EGFR) or notch intracellular domain (NICD) (Figure S2). Thus, our observations suggest that, *Drosophila* 7SK snRNP complex may function, specifically, to repress tumorigenic potential of Yki *in vivo* in an epithelial tumor model.

**Components of the NELF complex may function as tumor suppressors**

The NELF complex is composed of four subunits: NELF-A, -B, -C/-D and -E. Depletion of each of the NELF components using RNAi in combination with Yki also produced a giant larval phenotype (Figure 1B) and massively overgrown wing disc tissue compared to the larvae overexpressing only Yki (Figure...
Depletion of the NELF components on their own did not cause such giant larval phenotype or overgrowth of the wing disc tissue (Figure S1). These components too did not show any tumor phenotype in the context of overexpressed EGFR or NICD (Figure S2).

It was intriguing to find multiple components of the two spatio-temporally separated protein complexes, involved in the regulation of transcription elongation, among the tumor suppressors identified in a genome-wide screen for factors cooperating with Yki in growth regulation (Groth et al. 2019).

**Neoplastic transformation induced by Yki combined with depletion of 7SK snRNP or NELF complexes**

Yki is known to promote cell proliferation and cell survival. Thus, it is possible that larger size of the wing disc tissue observed upon loss of either 7SK snRNP or NELF complex is a result of enhancement of growth and survival effect of Yki, and not a neoplastic transformation. To distinguish between the two possibilities, we analyzed the tumor tissue using markers that indicate neoplastic transformation.

First, we examined epithelial cell polarity. Neoplastic transformation of an epithelial tissue is accompanied by the loss of their characteristic apico-basal cell polarity. E-cadherin (E-Cad) is a subapically localized protein that provides a convenient marker for epithelial polarization (Tanos and Rodriguez-Boulan 2008). Wing discs overexpressing Yki alone showed localization of E-Cad, in a pattern similar to the wild-type wing discs, although the former discs are much larger (Figure 2A). This indicated that Yki overexpression caused overgrowth of the epithelium without perturbation of epithelial cell polarity. In contrast, when Yki overexpression was combined with depletion of a component of the 7SK snRNP complex or the NELF complex, subapical localization of E-cad was lost or perturbed (Figure 2A). Additionally, we analyzed F-Actin, which localizes near the apical junctions of the wing disc epithelial cells, using rhodamine-labeled phalloidin. As with E-Cad, we observed loss of apical localization of F-Actin in the Yki expressing tissue depleted of a component of the 7SK snRNP or the NELF complex, but not in wing disc tissue expressing Yki alone (Figure S3). We did not observe any change in cell polarity, as indicated by E-Cad or F-Actin localization in wing discs with depletion of components of 7SK snRNP and NELF complexes alone (Figure S4A; data not shown for F-Actin).

The matrix metallo-protease MMP1 has been used as a marker of epithelial to mesenchymal transition (EMT) and neoplastic transformation in *Drosophila* tumor models. MMP1 expression is elevated in tumor models and its depletion by RNAi has been reported to block metastasis (Uhlirova and Bohmann 2006; Beaucer et al. 2007; Miles et al. 2011). We examined the effects of depleting components of 7SK snRNP and NELF complexes in Yki-expressing tissue on the levels of MMP1 by immunohistochemistry. We observed significantly elevated levels of MMP1 in wing discs
overexpressing Yki and depleted for Bin3, Hexim, or the NELF complex (Figure 2B, Figure S5A). We observed only marginal increase (statistically insignificant) in MMP1 levels in wing discs expressing Yki alone (Figure 2B, Figure S5A). We did not observe any detectable change in the intensity of MMP1 levels in the wing discs depleted for the components of 7SK snRNP and NELF complexes alone (Figure S4B and Figure S5B).

Taken together, tumors formed upon depletion of 7SK snRNP or NELF complex components in combination with Yki exhibit neoplastic characters. As neither genetic change alone produced these results, it appears that they act in combination to promote neoplasia, a classical mechanism of cooperative tumorigenesis as known in mammals. These observations provide evidence that the activity of 7SK snRNP and NELF complexes may have a tumor-suppressing function, but only in the context of elevated Yki activity.

**CDK9 is required for Yki-mediated tumorigenesis**

The 7SK snRNP and NELF complexes help in maintaining the paused state of RNA Pol II. Our findings raised the question of whether pausing of RNA Pol II per se served to limit the tumor promoting potential of Yki activity. If this is the case,
we reasoned that using an alternative means to release RNA Pol II should also lead to tumorigenesis in the context of Yki overexpression. The P-TEFb complex, comprising cycl/T/CDK9, is required for release of paused RNA Pol II and effective elongation of mRNA. CDK9 phosphorylates the NELF complex, leading to eviction of NELF from the pause site. This in turn facilitates release of paused RNA Pol II, aiding in productive elongation. CDK9 also acts directly on RNA Pol II, phosphorylating it on S5 in the C-terminal domain, a known mark of elongating RNA Pol II (Jennings 2013). As the P-TEFb complex is normally rendered inactive through sequestration by 7SK snRNP complex, we hypothesized that overexpressing CDK9 might bypass normal regulation of pausing, leading to inactivation of NELF complex and RNA Pol II release. Consistent with this hypothesis, we indeed observed massive tissue overgrowth when Yki was co-expressed with CDK9, while overexpression of CDK9 alone did not cause any such phenotype (Figure 3A). Such overgrowth phenotype was not observed when CDK9 was overexpressed in the background of elevated activities of EGFR or Notch (Figure S2). This suggests that PPP-mediated regulation of growth is Yki-specific.

Wing discs expressing UAS-CDK9 together with UAS-Yki also showed loss of apically localized E-Cad as well as elevated MMP1 expression (Figure 3B), compared to tissue expressing UAS-CDK9 alone or UAS-Yki alone. This indicates neoplastic transformation in wing discs co-expressing Yki and CDK9, similar to the transformation caused by depletion of 7SK snRNP and NELF complex components in combination with overexpressed Yki.

As further test of this model, we asked whether CDK9 is essential for tumorigenic cooperation between depletion of 7SK snRNP complex components and Yki. Depletion of cdk9 effectively suppressed the tissue overgrowth caused by depleting bin3 or Hexim in Yki expressing tissue (Figure 4A). Those wingdiscs also showed normal apical localization of E-Cad and wildtype levels of MMP1 expression, suggesting complete suppression of tumorous growth (Figure 4, B and C).

Given that CDK9 is known to act directly on both NELF proteins and RNA Pol II, we wondered whether CDK9 activity would be required in the absence of the NELF complex. As shown above in the case of removing the 7SK snRNP complex, depletion of cdk9 suppressed overgrowth caused by RNAi-mediated depletion of NelfA and overexpression of Yki (Figure 4A). This was accompanied by restoration of apico-basal polarity and MMP1 expression to wild-type levels (Figure 4, B and C). This finding provides evidence that alleviation of pausing by removal of NELF complex is not sufficient without CDK9 activity. This presumably reflects an importance of activation of RNA Pol II by CDK9-mediated phosphorylation.

We then examined if depletion of the complexes associated with PPP and increased CDK9 levels are sufficient to cause overgrowth phenotype, or whether the growth is tightly coupled to the presence of a growth driver such as Yki. Depletion of components of 7SK snRNP or NELF complexes in the background of overexpressed CDK9 did not cause any growth phenotype or morphological alteration in wing disc epithelium (Figure 5). This suggests that deregulation of RNA Pol II pausing is not sufficient on its own to produce an overgrowth or neoplastic phenotype; yet it does so in the context of Yki overexpression. In the context of elevated Yki activity, there appear to be two brakes, each of which must be removed by CDK9 activity to allow excess Yki to produce tumors in Drosophila wing disc tissue.

**Tumorigenesis induced by alleviation of pausing is associated with deregulated proteostasis**

As overexpression of Yki was essential, although not sufficient, to cause neoplastic tumors, genetic experiments above provided an opportunity to distinguish between Yki-activated genes that cause simple hyperplastic growth of the discs (when Yki is overexpressed in a wild-type background) vs. causing neoplastic growth (when Yki is overexpressed along with depletion of bin3, Hexim, or NELFs).

We carried out RNA-seq to identify differentially expressed genes in discs depleted for NelfA and overexpressing Yki as well as both individual treatments. We also carried out RNA-seq for GFP expressing wild-type wing discs as a control. We find that transcripts corresponding to 776 genes were uniquely upregulated (Figure 6A) and 1009 genes were uniquely downregulated (Figure 6B) in the tumorous wing discs (ap > UAS-Yki; UAS-NelfARNAi), compared to all other genotypes including wild-type discs (noncoding transcripts are not included in this estimation). When compared to the list of direct targets of Yki (reported by based on ChIP-seq data), we find 38 (4.9%) of the upregulated genes and 84 (8.3%) of the downregulated genes are presumptive direct targets of Yki (Table S1).

We also observed an enhancement of effect of Yki (compared to wildtype discs) in a subset of transcripts that were common to nontumorous tissue overexpressing Yki alone (ap > UAS-Yki) and tumors ap > UAS-Yki; UAS-NelfARNAi.
tissue. We reasoned that since PPP functions to attenuate expression of genes, identifying transcripts whose expression is further up- or downregulated in ap^UAS-Yki; UAS-NelfARNAi tissue (compared to ap^UAS-Yki) may give a better indication of the role of PPP in Yki-mediated growth. We find that transcripts corresponding to 155 genes that are upregulated in both nontumorous ap^UAS-Yki discs and tumorous ap^UAS-Yki; UAS-NelfARNAi discs, but degree of enhancement was higher in tumorous tissue. Likewise, these transcripts corresponding to 160 genes, whose expression was downregulated compared to wildtype discs, were common to both nontumorous and tumorous tissue, but degree of downregulation was higher in tumorous tissue. Interestingly, 31 (20%) of these upregulated genes (n = 155) and 35 (21.9%) of downregulated genes were presumptive direct targets of Yki that are regulated by PPP and misregulated due to RNAi medicated knockdown of many components of the pausing machinery.

We observed enrichment for pathways involved in ribosome and its biogenesis in the upregulated set (Table 1 and Figure 6). Interestingly, protein processing in endoplasmic reticulum, regulators of proteasome function, and different components of proteasome were enriched among genes downregulated in tumorous tissues (Table 2). These observations indicate overall deregulation of protein homeostasis (proteostasis) in tumors caused by depletion of NelfA in combination with Yki overexpression, consistent with recent data on human cancers (Ruggero 2013; Pelletier et al. 2017).

**Discussion**

PPP has emerged as a critical regulatory step in gene expression (Core and Adelman 2019). It involves stalling of RNA Pol II 20–60 nucleotides downstream of the transcription start site, and controlled release of RNA Pol II when triggered by signals from the surroundings. Many studies in recent years have elucidated mechanisms by which RNA Pol II is stalled and the factors that bring about pausing as well as release of the paused RNA Pol II. Our in vivo model for tumorigenesis has allowed us to elucidate the functions of the NELF, 7SKsnRNP, and P-TEFb complexes in the context of growth control in vivo. Previous studies have implicated NELF in regulating the response of embryonic stem cells to signaling cues such as fibroblast growth factor (FGF; Williams et al. 2015). Furthermore, PPP has been shown to be important for coordination of expression genes involved in morphogenesis of Drosophila embryo (Lagha et al. 2013). Our findings provide direct evidence that PPP can limit tumor

### Table 1 List of genes whose expression is upregulated in the wing discs of ap-GAL4/UAS-NelfA^RNAi; UAS-Yki

| Aminoacyl-tRNA biosynthesis | Ribosome | Ribosome biogenesis in eukaryotes |
|-----------------------------|----------|----------------------------------|
| Gene name logFC | Gene name logFC | Gene name logFC |
| Slimp 2.124626 | Rpl24-like 1.256082 | Non1 2.292457 |
| Aats-leu 1.413973 | Rpl5 1.202779 | Ns2 0.900983 |
| Aats-thr 0.912237 | Rpl15 1.130382 | RIOK1 1.354352 |
| Aats-cys 0.813931 | mRpl28 0.969423 | CG12301 0.997310 |
| Aats-tyr-m 1.047766 | mRpl9 0.799329 | Bka 0.876333 |
| Aats-pro 1.07342 | RpS17 0.82044 | eIF6 0.745744 |
| Aats-ile 0.73741 | mRpl35 0.997681 | I(3)T2Dn 0.800876 |
| CG4573 1.138148 | Rpl23 0.782542 | CG8064 0.778604 |
| CG1750 1.487797 | Rps4 0.775449 | Nmd3 0.716537 |
| CG6796 0.925494 | Rpl27A 0.716573 | Mat89Ba 0.713426 |
| CG7441 0.884721 | Rpl32 0.681588 | CG11920 0.750235 |
| CG17259 0.726080 | Rpl40 0.674508 | CG3071 0.713535 |
| Aats-trp 0.732224 | Rps29 0.743389 | CG33158 0.595732 |
| Aats-asp 0.747097 | Rpl26 0.620538 | CG13185 0.823244 |
| Aats-gly 0.613889 | mRpl10 0.692489 | CG7246 0.798345 |
| CG5463 1.037030 | mRpl3 0.671734 | CG8549 0.593618 |
| Aats-ala-m 0.602770 | Rpl35 0.631348 | |
| CG5660 0.663614 | Rpl27 0.594275 | |
| | Rpl28 0.629209 | |
| | Rpl21 0.600412 | |
| | Rpl22-like 1.081389 | |
| | RpS3A 0.587288 | |
| | RpL37A 0.3662 | |
| | mRpl11 0.624297 | |
formation in the context of the Hippo tumor suppressor pathway. Depletion of these factors alone, or even in combination with overexpression of CDK9, was not sufficient to induce tumorous growth but did so when combined with overexpression of Yki. This cooperation appears to be specific to Yki-induced tumors as there was no cooperation with other oncogenic drivers such as EGFR or activated Notch in wing disc tumor models. This suggests that pausing plays a previously unappreciated role regulating the output of Hippo pathway in growth control, thereby limiting its tumorigenic potential.

We were intrigued by the finding that CDK9 activity is required for Yki-driven tumor formation, even when the upstream and downstream pausing complex factors have been removed. These observations suggest that CDK9 activity is

| Gene name | logFC | Gene name | logFC |
|------------|-------|------------|-------|
| Rpn7       | −1.084698 | prtp       | −1.46289 |
| Rpn13      | −0.949757  | Sec61gamma | −1.65593 |
| Rpn2       | −0.900781  | Sec61beta  | −1.31964 |
| Prosalpha3 | −0.910536  | CG5885     | −1.28449 |
| Rpn3       | −0.850895  | Sec61alpha | −1.25184 |
| Rpn1       | −0.879125  | TRAM       | −1.3381 |
| Pomp       | −0.795409  | Pdi        | −1.145 |
| Prosalpha5 | −0.834712  | SsRbeta    | −1.23571 |
| Prosbeta4  | −0.76685   | Sec13      | −1.01315 |
| Prosbeta7  | −0.717883  | Sec63      | −0.97489 |
| Prosbeta2  | −0.706638  | CG14476    | −1.03296 |
| Prosbeta5  | −0.687177  | Sec24CD    | −0.87522 |
| Prosalpha4 | −0.694159  | Ostgamma   | −0.97374 |
| Prosbeta6  | −0.631819  | Ost48      | −0.88256 |
| Rpn10      | −0.592037  | CG4164     | −1.21065 |
| Rpn12      | −0.597364  | ergic53    | −0.86625 |

Promoter Proximal Pausing and Yki
required not only to remove the "brake" exerted by NELF
pausing complex, but also required to increase RNA Pol II
activity through direct phosphorylation. Neither alone is suf-
ficient. This suggests an overlapping "belt and suspenders"
regulation to ensure that expression of Yki targets is main-
tained at appropriate levels for normal growth control, while
preventing overexpression, which may lead to tumorigenesis.
A mechanism of this sort allows for the possibility that other
growth regulatory or metabolic homeostasis pathways might
impact on the outcome of Yki activity via regulation of the
CDK9. Indeed, evidence of a role for CDK9 in YAP/TAZ-
mediated cell growth via regulation of a subset of YAP/TAZ
target genes in mammalian liver cells has been demonstrated
(Galli et al. 2015). Inhibition of CDK9 activity using flavopir-
idol nullified the effect of YAP S127A mutant form (the con-
stitutively active form of YAP) on the expression of YAP target
genes studied (Galli et al. 2015). Although this observation is
not validated in fly tissues, perhaps PPP (including 7skRNP-,
CDK9-, and NELFs-) dependent regulation of Yki is indepen-
dent of the phosphorylation status of Yki, which implies a
parallel function for PPP rather than it being upstream of Yki.

Our genetic model is also useful to study the importance of
PPP in attenuating transcriptional output at genome wide
scale. Preliminary observations of data generated by RNA-seq
suggest that most genes that are differentially expressed when
Yki is overexpressed show further changes in the same di-
rection (up or down regulation) in combination of Yki over-
expression with depletion of Nelf-A. Furthermore, we also
report deregulation of proteostasis uniquely in tumor tissue.
This is consistent with recent reports that deregulation of
translation and deregulation of protein processing are
important factors in progression of cancers and might be
target for therapy (Ruggero 2013; Pelletier et al. 2017).

To conclude, our study has highlighted additional regulat-
ory module on Yki driven tumorigenic activity, which im-
pinges directly on transcription. It will be interesting to see the
role of the PPP machinery, which has been reported to be
highly conserved from Drosophila to humans (Peterlin and
Price 2006), in the context of highly conserved Hippo path-
way effectors YAP/TAZ. Considering the reported function of
CDK9 in YAP-driven transcription, and the therapeutic acces-
sibility of CDK9 activity (Galli et al. 2015; Blake et al. 2019), it
is critical to understand the function of 7SK snRNP and NELF
complexes in this context.

Acknowledgments

We thank G. Deshpande and members of the LSS and SMC
laboratories for critical input. This work was supported
primarily by an Indo-Danish research grant from the Depart-
ment of Biotechnology, Government of India to L.S.S. and
from the Innovation fund Denmark, Novo Nordisk Foundation
NNF12OC0000552 and Neye Foundation to SMC; a JC
Bose Fellowship and grant from the Department of Science
and Technology, Government of India to LSS; and a Univer-
sity Grants Commission (UGC) Research Fellowship to SN.

Author contributions: S.N., P.G. and R.W. carried out all fly
experiments. S.N. did RNA-seq and its analysis, all image
analyses, and wrote the MS. L.S.S. and SM conceived the
project and wrote the MS. We declare “no-conflict-of-interest”.

Note added in proof: See Groth et al. 2020 (pp. 2999–3008)
in G3 10:9 for a related work.

Literature Cited

Anders, S., and W. Huber, 2010 Differential expression analysis
for sequence count data. Genome Biol. 11: R106. https://
doi.org/10.1186/gb-2010-11-10-r106
Beaucher, M., E. Hersperger, A. Page-McCaw, and A. Sheam, 2007 Met-
astatic ability of Drosophila tumors depends on MMP activity. Dev.
Biol. 303: 625–634. https://doi.org/10.1016/j.ydbio.2006.12.001
Blake D. R., A. V. Vaseva, R. G. Hodge, M. P. Kline, T. S. K. Gilbert et al.,
2019 Application of a MYC degradation screen identifies sensitivity
to CDK9 inhibitors in KRAS-mutant pancreatic cancer. Sci. Signal.
12: ena7259. https://doi.org/10.1126/scisignal.7259
Cohen, B., M. E. McGuffin, C. Pleifile, D. Segal, and S. M. Cohen, 1992 apterus, a gene required for imaginal disc development in Drosophila encodes a member of the LiM family of develop-
mental regulatory proteins. Genes Dev. 6: 715–729. https://
doi.org/10.1101/gad.6.5.715
Core L., and K. Adelman, 2019 Promoter-proximal pausing of
RNA polymerase II: a nexus of gene regulation. Genes Dev.
33: 960–982. https://doi.org/10.1101/gad.325142.119
Dong, J., G. Feldmann, J. Huang, S. Wu, N. Zhang et al., 2007 Elucidation
of a universal size-control mechanism in Drosophila and mammals.
Cell 130: 1120–1133. https://doi.org/10.1016/j.cell.2007.07.019
Galli, G. G., M. Carrara, W. C. Yuan, C. Valdes-Quezada, B. Gurung
et al., 2015 YAP drives growth by controlling transcriptional
pause release from dynamic enhancers. Mol. Cell 60: 328–337.
https://doi.org/10.1016/j.molcel.2015.09.001
Gateff, E., T. Löffler, and J. Wismar, 1993 A temperature-sensitive
brain tumor suppressor mutation of Drosophila melanogaster: de-
velopmental studies and molecular localization of the gene. Mech.
Dev. 41: 15–31. https://doi.org/10.1016/0925-4773(93)90052-Y
Groth, C., P. Vaid, A. Khatpe, N. Prashali, A. Ahilya et al., 2020 Genome-wide screen for context-dependent tumor sup-
pressors identified using in vivo models for neoplasia in Dro-
sophila. G3 (Bethesda) DOI: 10.1534/g3.120.401545.
Guenther, M. G., S. S. Levine, L. A. Boyer, R. Jaenisch, and R. A.
Young, 2007 A chromatin landmark and transcription initia-
tion at most promoters in human cells. Cell 130: 77–88. https://
doi.org/10.1016/j.cell.2007.05.042
Huang, J., S. Wu, J. Barrera, K. Matthews, and D. Pan, 2005 The
Hippo signaling pathway coordinates regulates cell proliferation
and apoptosis by inactivating Yorkie, the Drosophila homolog of
YAP. Cell 122: 421–434. https://doi.org/10.1016/j.cell.2005.06.007
Jennings, B. H., 2013 Pausing for thought: disrupting the early
transcription elongation checkpoint leads to developmental de-
fects and tumorigenesis. BioEssays 35: 553–560. https://
doi.org/10.1002/bies.201200179
Johnson, R., and G. Halder, 2014 The two faces of Hippo: targeting the
Hippo pathway for regenerative medicine and cancer treatment. Nat.
Rev. Drug Discov. 13: 63–79. https://doi.org/10.1038/nrd4161
Jonkers, I., and J. T. Lis, 2015 Getting up to speed with transcrip-
tion elongation by RNA polymerase II. Nat. Rev. Mol. Cell Biol.
16: 167–177. https://doi.org/10.1038/nrm3953
Kanazawa, S., L. Soucek, G. Evan, T. Okamoto, and B. M. Peterlin,
2003 c-Myc recruits P-TEFb for transcription, cellular prolifera-
tion and apoptosis. Oncogene 22: 5707–5711. https://doi.org/
10.1038/sj.onc.1206800

76  S. Nagarkar et al.
